Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
44,162,869
-
Number of holders
-
50
-
Total 13F shares, excl. options
-
31,821,580
-
Shares change
-
-914,583
-
Total reported value, excl. options
-
$210,332,653
-
Value change
-
-$5,208,246
-
Number of buys
-
18
-
Number of sells
-
-29
-
Price
-
$6.61
Significant Holders of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) as of Q3 2022
63 filings reported holding PRLD - Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share as of Q3 2022.
Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) has 50 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31,821,580 shares
of 44,162,869 outstanding shares and own 72% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (10,123,824 shares), ORBIMED ADVISORS LLC (10,039,691 shares), FMR LLC (4,638,532 shares), UBS ASSET MANAGEMENT AMERICAS INC (2,402,595 shares), VANGUARD GROUP INC (899,045 shares), HHLR ADVISORS, LTD. (583,333 shares), MASSACHUSETTS FINANCIAL SERVICES CO /MA/ (513,293 shares), BlackRock Inc. (459,134 shares), PRICE T ROWE ASSOCIATES INC /MD/ (313,165 shares), and MORGAN STANLEY (177,710 shares).
This table shows the top 50 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.